

APPLICANTS: Moses Rodriguez, et al.  
SERIAL NO. : 08/692,084  
FILED : August 8, 1996  
Page 2

and February 27, 1996, respectively, under the terms of the Budapest Treaty, with the American Type Culture Collection (ATCC) and given ATCC Accession Nos. CRL 11627 and HB12057, respectively" with -- [Cell, SCH94.03 was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd, Manassas, VA 20110-2209 on April 28, 1994 and was given ATCC designation CRL11627. Cell, SCH79.08 was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd, Manassas, VA 20110-2209 on, February 27, 1996 and was given ATCC designation HB 1205] --

**IN THE CLAIMS:**

Please amend claims 1, 9, and 19 under the provisions of 37 C.F.R. § 1. 121(b) by deleting the bracketed word or words and inserting the underlined word or words as follows:

*B2 Subj*  
1. (Twice Amended) A method of stimulating remyelination of central nervous system axons in a mammal which comprises administering to said mammal an effective amount of [a] an [monoclonal] autoantibody selected from the group consisting of [mAb] SCH 94.03, SCH 79.08, O1, O4, A2B5, HNK-1, antigen binding fragments thereof, and isolated or synthetic [autoantibodies having the characteristics thereof] autoantibody capable of inducing remyelination of central nervous system axons.

*B3 Subj E3*  
9. (Twice Amended) A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of [a] an [monoclonal] autoantibody selected from the group consisting of [mAb] SCH 94.03, SCH 79.08, O1, O4, A2B5, HNK-1, antigen binding fragments thereof, and isolated or synthetic [autoantibodies having the characteristics thereof] autoantibody capable of inducing remyelination of central nervous system axons.

*B4 Subj E5*  
19. (Twice Amended) A pharmaceutical composition comprising as the active agent, an antigen binding fragment of [a] an [monoclonal] autoantibody selected from the group consisting of [mAb] SCH94.03, SCH79.08 [, HNK-1], and isolated or synthetic [autoantibodies having the characteristics of mAb SCH94.03, SCH79.08, O1, O4, A2B5 or HNK-1] autoantibody capable of inducing remyelination of central nervous system axons.

**REMARKS**

Entry of the foregoing and further and favorable reconsideration of the subject application in light of the foregoing amendment and the following remarks, pursuant to and consistent with 37 C.F.R. §1. 112 are respectfully requested.